Treat-to-target in PsA: methods and necessity.
health services research
psoriatic arthritis
treatment
Journal
RMD open
ISSN: 2056-5933
Titre abrégé: RMD Open
Pays: England
ID NLM: 101662038
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
16
12
2019
revised:
20
01
2020
accepted:
05
02
2020
entrez:
20
2
2020
pubmed:
20
2
2020
medline:
20
4
2021
Statut:
ppublish
Résumé
With increasing recognition of the high burden and impact of psoriatic arthritis (PsA) and the growing number of therapeutic options, there has been an intensifying focus on treatment strategy in recent years. In 2015, the Tight Control of Psoriatic Arthritis study confirmed the clinical benefit of using a treat-to-target approach in PsA. This randomised controlled trial found benefits in both arthritis and psoriasis disease activity as well as lower disease impact reported by patients, although participants allocated to tight control experienced a higher rate of serious adverse events. European and international recommendations support the use of a treat-to-target approach in PsA and have offered specific advice on how to do this using outcomes such as the minimal disease activity criteria. However, implementation of this approach in routine practice is low, with real-world data highlighting undertreatment as a result. Recent qualitative work with physicians in the UK has helped researchers to understand the barriers to implementation of treat-to-target in PsA. We now need to address these barriers, provide education and support to non-specialist clinicians in routine practice, and aid the translation of optimal care to the clinic.
Identifiants
pubmed: 32071281
pii: rmdopen-2019-001083
doi: 10.1136/rmdopen-2019-001083
pmc: PMC7046962
pii:
doi:
Substances chimiques
Antirheumatic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Department of Health
ID : CS-2016-16-016
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Arthritis Care Res (Hoboken). 2016 Feb;68(2):267-74
pubmed: 25779603
Ann Rheum Dis. 2019 Feb;78(2):201-208
pubmed: 30442648
Ann Rheum Dis. 2020 Aug;79(8):1031-1036
pubmed: 32424031
Ann Rheum Dis. 2017 Feb;76(2):418-421
pubmed: 27457512
Arthritis Rheumatol. 2017 Jul;69(7):1374-1380
pubmed: 28512998
Semin Arthritis Rheum. 2016 Aug;46(1):81-7
pubmed: 27058970
Ann Rheum Dis. 2016 Mar;75(3):499-510
pubmed: 26644232
Arthritis Res Ther. 2017 Oct 10;19(1):226
pubmed: 29017591
N Engl J Med. 1993 Sep 30;329(14):977-86
pubmed: 8366922
Ann Rheum Dis. 2010 Jan;69(1):48-53
pubmed: 19147615
J Rheumatol. 2016 Feb;43(2):371-5
pubmed: 26669918
Implement Sci. 2007 Aug 16;2:27
pubmed: 17705824
Lancet. 1998 Jun 13;351(9118):1755-62
pubmed: 9635947
BMJ Qual Saf. 2014 Apr;23(4):290-8
pubmed: 24025320
Arthritis Care Res (Hoboken). 2018 Oct;70(10):1529-1535
pubmed: 29409133
Rheumatology (Oxford). 2003 Dec;42(12):1460-8
pubmed: 14523223
J Rheumatol. 2001 Aug;28(8):1842-6
pubmed: 11508587
Arthritis Care Res (Hoboken). 2018 Dec;70(12):1771-1777
pubmed: 29609210
Lancet. 2004 Jul 17-23;364(9430):263-9
pubmed: 15262104
Arthritis Rheumatol. 2018 Mar;70(3):345-355
pubmed: 29193765
Arthritis Res Ther. 2017 Mar 29;19(1):72
pubmed: 28356155
Rheumatology (Oxford). 2018 Feb 1;57(2):283-290
pubmed: 28541484
Ann Rheum Dis. 2016 Apr;75(4):640-3
pubmed: 26672066
Ann Rheum Dis. 2017 Jun;76(6):960-977
pubmed: 28264816
J Rheumatol. 1990 Jun;17(6):809-12
pubmed: 2388203
Arthritis Care Res (Hoboken). 2010 Jul;62(7):965-9
pubmed: 20589696
Arthritis Care Res (Hoboken). 2018 Oct;70(10):1551-1556
pubmed: 29316341
Arthritis Rheum. 1998 Jun;41(6):1103-10
pubmed: 9627021
Ann Rheum Dis. 2016 May;75(5):811-8
pubmed: 26269398
J Rheumatol. 2014 Jul;41(7):1357-65
pubmed: 24931949
Lancet. 2015 Dec 19;386(10012):2489-98
pubmed: 26433318